gamma vaccines pty limited

Press Release

22 June 2011

We are pleased to announce the appointment of Dr Ken Tempero as a Director of Gamma Vaccines. Ken brings a wealth of pharmaceutical and business experience to the company. He was responsible for the design and conduct of Phase I (first time in man) trials at Merck and Co., Inc as well as overseeing Merck's international Phase II – IV clinical programs. He then joined G. D. Searle and Co., Inc as Vice-President with responsibility for worldwide clinical operations. He then moved to the Biotech sector, being appointed Chairman and CEO of MGI PHARMA. Ken successfully steered MGI through a period of extensive restructuring, identification of promising intellectual property, establishment of international partnerships, the generation and codification of data leading to the approval of its first New Drug Application (NDA) to the US FDA and the creation of MGI PHARMA'S proprietary sales force. MGI PHARMA was subsequently acquired by Elsai Co.of Japan for $3.9B all cash transaction.

Ken will serve as an independent non-executive director on Board of Gamma Vaccines. He will assume roles traditionally reserved for such appointments, as well bringing a valuable North American and global perspective on the management of clinical trials.

Professor Tim Hirst, Executive Chairman of Gamma Vaccines commented "I am delighted that Dr Tempero has accepted our invitation to become a director. He brings a life-time of experience in both big pharma and biotech companies and a wealth of knowledge of clinical trial management and regulatory submissions. I very much look forward to working with him".

More information about Dr Ken Tempero can be found at www.gammavaccines.com [People].

For Further Information, please contact Tim Hirst on +61 420 942 824

About Gamma Vaccines

Gamma Vaccines is headquartered in Canberra, Australia. It was established in 2009 to develop GammaFlu®, a universal flu vaccine that is expected to do away with the need to produce new influenza vaccines each year. GammaFlu® is also being designed to be effective against any new pandemic strain, enabling it to be stockpiled and used as an immediate emergency response to any new influenza pandemic.

Professor Tim Hirst
Executive Chairman
+61 (0) 420 942 824
tim@gammavaccines.com

www.gammavacines.com

Gamma Vaccines Pty Ltd
PO Box 4435 Manuka
ACT 2603
ABN 32 138 479 151